Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) Will Announce Quarterly Sales of $550,000.00

Analysts expect VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) to post sales of $550,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for VYNE Therapeutics’ earnings, with estimates ranging from $300,000.00 to $800,000.00. VYNE Therapeutics reported sales of $4.12 million in the same quarter last year, which indicates a negative year-over-year growth rate of 86.7%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that VYNE Therapeutics will report full-year sales of $4.20 million for the current year, with estimates ranging from $1.00 million to $10.00 million. For the next year, analysts expect that the business will post sales of $7.27 million, with estimates ranging from $800,000.00 to $20.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover VYNE Therapeutics.

VYNE Therapeutics (NASDAQ:VYNE – Get Rating) last released its quarterly earnings results on Thursday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.22). VYNE Therapeutics had a negative net margin of 496.98% and a negative return on equity of 106.54%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.09 million.

VYNE has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of VYNE Therapeutics in a research note on Friday, March 18th. Zacks Investment Research raised shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, April 13th.

VYNE Therapeutics stock opened at $0.45 on Friday. The company’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.88. VYNE Therapeutics has a 1 year low of $0.44 and a 1 year high of $5.47. The stock has a market capitalization of $25.21 million, a P/E ratio of -0.31 and a beta of 0.96.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. DSC Advisors L.P. boosted its stake in VYNE Therapeutics by 131.9% during the 4th quarter. DSC Advisors L.P. now owns 2,551,000 shares of the company’s stock worth $2,602,000 after purchasing an additional 1,451,000 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of VYNE Therapeutics by 1.1% during the 3rd quarter. Franklin Resources Inc. now owns 1,921,236 shares of the company’s stock valued at $2,671,000 after acquiring an additional 20,373 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of VYNE Therapeutics by 300.4% during the 3rd quarter. Renaissance Technologies LLC now owns 1,245,027 shares of the company’s stock valued at $1,731,000 after acquiring an additional 934,100 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of VYNE Therapeutics by 135.7% during the 4th quarter. GSA Capital Partners LLP now owns 217,747 shares of the company’s stock valued at $222,000 after acquiring an additional 125,345 shares during the last quarter. Finally, Morgan Stanley boosted its position in shares of VYNE Therapeutics by 438.6% during the 2nd quarter. Morgan Stanley now owns 203,075 shares of the company’s stock valued at $713,000 after acquiring an additional 165,372 shares during the last quarter. 26.73% of the stock is currently owned by institutional investors.

VYNE Therapeutics Company Profile (Get Rating)

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.

Recommended Stories